Corpus overview


Overview

MeSH Disease

Human Phenotype

Transmission

Seroprevalence
    displaying 1 - 10 records in total 11
    records per page




    Analysis of Characteristics and Causes of Anemia HP Anemia MESHD in 46 Severe and Critically Severe COVID-19 Patients

    Authors: WU Yu Han1*, Meng Shan Shan1, Che Chun Li1#; Che Chun Li; Meng Shan Shan

    doi:10.21203/rs.3.rs-71864/v1 Date: 2020-09-03 Source: ResearchSquare

    Background:By analyzing characteristics and causes of anemia HP anemia MESHD in 46 severe and critically severe COVID-19 patients that we treated, we aim to provide information on pathogenesis and the treatment method of COVID-19.Methods: A retrospective analysis was performed on clinical data and laboratory findings of patients confirmed with severe and critically severe COVID-19. They were treated in Severe COVID-19 Treatment Center in Heilongjiang during the period of February 12, 2020 to March 19, 2020. We clarified the type of anemia HP anemia MESHD and explored the relationship between novel coronavirus infection MESHD, therapeutic drugs and anemia HP anemia MESHD.Results: Among the 50 COVID-19 patients, 46 patients suffered from normocytic autoimmune hemolytic anemia HP autoimmune hemolytic anemia MESHD. The occurrence and severity of anemia HP anemia MESHD was irrelated to changes in titer of novel coronavirus IgM and IgG antibodies SERO (r=0.071, P=0.897; r =0.41, P=0.361). The changes of the average Hb concentration and the changes of average drug concentration of patients with anemia HP anemia MESHD showed that anemia HP anemia MESHD had a significant negative correlation with Arbidol (r=- 0.758, P=0.029), but no significant correlation with Ribavirin, Interferon α-2b and magnesium isoglycyrrhizinate(P>0.05).Conclusion: Severe and critically severe COVID-19 patients are more likely to have AIHA. Arbidol is significantly associated with AIHA in severe and critically severe COVID-19 patients.

    Prior diagnoses and medications as risk factors for COVID-19 in a Los Angeles Health System

    Authors: Timothy S Chang; Yi Ding; Malika K Freund; Ruth Johnson; Tommer Schwarz; Julie M Yabu; Chad Hazlett; Jeffrey N Chiang; Ami Wulf; - UCLA Health Data Mart Working Group; Daniel H Geschwind; Manish J Butte; Bogdan Pasaniuc

    doi:10.1101/2020.07.03.20145581 Date: 2020-07-04 Source: medRxiv

    With the continuing coronavirus disease MESHD 2019 (COVID-19) pandemic coupled with phased reopening, it is critical to identify risk factors associated with susceptibility and severity of disease in a diverse population to help shape government policies, guide clinical decision making, and prioritize future COVID-19 research. In this retrospective case-control study, we used de-identified electronic health records (EHR) from the University of California Los Angeles (UCLA) Health System between March 9th, 2020 and June 14th, 2020 to identify risk factors for COVID-19 susceptibility (severe acute respiratory distress syndrome coronavirus 2 MESHD respiratory distress HP syndrome coronavirus 2 (SARS-CoV-2) PCR test positive), inpatient admission, and severe outcomes (treatment in an intensive care unit or intubation). Of the 26,602 individuals tested by PCR for SARS-CoV-2, 992 were COVID-19 positive (3.7% of Tested), 220 were admitted in the hospital (22% of COVID-19 positive), and 77 had a severe outcome (35% of Inpatient). Consistent with previous studies, males TRANS and individuals older than 65 years old had increased risk of inpatient admission. Notably, individuals self-identifying as Hispanic or Latino constituted an increasing percentage of COVID-19 patients as disease severity escalated, comprising 24% of those testing positive, but 40% of those with a severe outcome, a disparity that remained after correcting for medical co-morbidities. Cardiovascular disease MESHD, hypertension HP hypertension MESHD, and renal disease MESHD were premorbid risk factors present before SARS-CoV-2 PCR testing associated with COVID-19 susceptibility. Less well-established risk factors for COVID-19 susceptibility included pre-existing dementia HP dementia MESHD (odds ratio (OR) 5.2 [3.2-8.3], p=2.6 x 10-10), mental health conditions ( depression MESHD OR 2.1 [1.6-2.8], p=1.1 x 10-6) and vitamin D deficiency MESHD (OR 1.8 [1.4-2.2], p=5.7 x 10-6). Renal diseases MESHD including end-stage renal disease MESHD and anemia HP anemia MESHD due to chronic renal disease MESHD were the predominant premorbid risk factors for COVID-19 inpatient admission. Other less established risk factors for COVID-19 inpatient admission included previous renal transplant (OR 9.7 [2.8-39], p=3.2x10-4) and disorders of the immune system (OR 6.0 [2.3, 16], p=2.7x10-4). Prior use of oral steroid medications was associated with decreased COVID-19 positive testing risk (OR 0.61 [0.45, 0.81], p=4.3x10-4), but increased inpatient admission risk (OR 4.5 [2.3, 8.9], p=1.8x10-5). We did not observe that prior use of angiotensin converting enzyme inhibitors or angiotensin receptor blockers increased the risk of testing positive for SARS-CoV-2, being admitted to the hospital, or having a severe outcome. This study involving direct EHR extraction identified known and less well-established demographics, and prior diagnoses and medications as risk factors for COVID-19 susceptibility and inpatient admission. Knowledge of these risk factors including marked ethnic disparities observed in disease severity should guide government policies, identify at-risk populations, inform clinical decision making, and prioritize future COVID-19 research.

    Red blood SERO cell distribution width (RDW) in Hospitalized COVID-19 Patients

    Authors: Preethi Ramachandran; Mahesh Gajendran; Abhilash Perisetti; Karim Osama Elkholy; Abhishek Chakraborti; Giuseppe Lippi; Hemant Goyal

    doi:10.1101/2020.06.29.20143081 Date: 2020-07-03 Source: medRxiv

    Introduction: Coronavirus disease-2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 MESHD (SARS-CoV-2), is causing dramatic morbidity and mortality worldwide. The Red Blood SERO Cell Distribution Width (RDW) has been strongly associated with increased morbidity and mortality in multiple diseases. Objective: To assess if elevated RDW is associated with unfavorable outcomes in hospitalized COVID-19. Methods: We retrospectively studied clinical outcomes of hospitalized COVID-19 patients for their RDW values. In-hospital mortality was defined as primary outcome, while septic shock MESHD shock HP, need for mechanical ventilation, and length of stay (LOS) were secondary outcomes. Results- A total of 294 COVID-19 patients were finally studied. Overall prevalence SERO of increased RDW was 49.7% (146/294). RDW was associated with increased risk of in-hospital mortality (aOR, 4.5; 95%CI, 1.4-14.3) and septic shock MESHD shock HP (aOR, 4.6; 95%CI, 1.4-15.1) after adjusting for anemia HP anemia MESHD, ferritin, and lactate. The association remained unchanged even after adjusting for other clinical confounders such as age TRANS, sex, body mass index, coronary artery disease MESHD, hypertension HP hypertension MESHD, diabetes mellitus HP diabetes mellitus MESHD, and chronic obstructive pulmonary disease HP chronic obstructive pulmonary disease MESHD. No association was found instead with mechanical ventilation and median LOS. Conclusion: Elevated RDW in hospitalized COVID-19 patients is associated with a significantly increased risk of mortality and septic shock MESHD shock HP.

    Factors Associated with Hospitalization and Disease Severity in a Racially and Ethnically Diverse Population of COVID-19 Patients

    Authors: Angelico Mendy; Senu Apewokin; Anjanette A Wells; Ardythe L Morrow

    doi:10.1101/2020.06.25.20137323 Date: 2020-06-26 Source: medRxiv

    Background: The coronavirus disease MESHD (COVID-19) first identified in Wuhan in December 2019 became a pandemic within a few months of its discovery. The impact of COVID-19 is due to both its rapid spread and its severity, but the determinants of severity have not been fully delineated. Objective: Identify factors associated with hospitalization and disease severity in a racially and ethnically diverse cohort of COVID-19 patients. Methods: We analyzed data from COVID-19 patients diagnosed at the University of Cincinnati health system from March 13, 2020 to May 31, 2020. Severe COVID-19 was defined as admission to intensive care unit or death MESHD. Logistic regression modeling adjusted for covariates was used to identify the factors associated with hospitalization and severe COVID-19. Results: Among the 689 COVID-19 patients included in our study, 29.2% were non-Hispanic White, 25.5% were non-Hispanic Black, 32.5% were Hispanic, and 12.8% were of other race/ethnicity. About 31.3% of patients were hospitalized and 13.2% had severe disease. In adjusted analyses, the sociodemographic factors associated with hospitalization and/or disease severity included older age TRANS, non-Hispanic Black or Hispanic race/ethnicity (compared to non-Hispanic White), and smoking. The following comorbidities: diabetes MESHD, hypercholesterolemia HP hypercholesterolemia MESHD, asthma HP asthma MESHD, COPD MESHD, chronic kidney disease HP chronic kidney disease MESHD, cardiovascular diseases MESHD, osteoarthritis HP osteoarthritis MESHD, and vitamin D deficiency MESHD were associated with hospitalization and/or disease severity. Hematological disorders MESHD such as anemia HP anemia MESHD, coagulation disorders MESHD, and thrombocytopenia HP thrombocytopenia MESHD were associated with both hospitalization and disease severity. Conclusion: This study confirms race and ethnicity as predictors of severe COVID-19. It also finds clinical risk factors for hospitalization and severe COVID-19 not previously identified such a vitamin D deficiency MESHD, hypercholesterolemia HP hypercholesterolemia MESHD, osteoarthritis HP osteoarthritis MESHD, and anemia HP anemia MESHD.

    Anemia HP Anemia MESHD and iron metabolism in COVID-19: A systematic review and meta-analysis

    Authors: Petek Eylul Taneri; Sergio Alejandro Gomez-Ochoa; Erand Llanaj; Peter Francis Raguindin; Lydia Z. Rojas; Beatrice Minder Wyssmann; Doris Kopp-Heim; Wolf E. Hautz; Michele F. Eisenga; Oscar H. Franco; Marija Glisic; Taulant Muka

    doi:10.1101/2020.06.04.20122267 Date: 2020-06-05 Source: medRxiv

    Iron metabolism and anemia HP anemia MESHD may play an important role in multiple organ dysfunction syndrome MESHD in Coronavirus disease MESHD 2019 (COVID-19). If confirmed, this has important implications for the more than 1.62 billion people estimated to have anemia HP anemia MESHD globally. We conducted a systematic review and meta-analysis to evaluate biomarkers of anemia HP anemia MESHD and iron metabolism (hemoglobin, ferritin, transferrin, soluble transferrin receptor, hepcidin, haptoglobin, unsaturated iron-binding capacity, erythropoietin, free erythrocyte protoporphyrine, and prevalence SERO of anemia HP anemia MESHD) in patients diagnosed with COVID-19, and explore their prognostic value. Six bibliographic databases were searched up to May 5th 2020. We included 56 unique studies, with data from 14,044 COVID-19 patients (59 years median age TRANS). Pooled mean hemoglobin and ferritin levels in COVID-19 patients across all ages TRANS were 130.41 g/L (95% Confidence Interval (CI), 128.42; 132.39) and 673.91 ng/mL (95% CI, 420.98; 926.84), respectively. Hemoglobin levels decreased with advancing age TRANS and increasing percentage of comorbid and critically ill MESHD patients, while levels of ferritin increased with increasing male TRANS proportion and mean hemoglobin levels. Compared to moderate cases, severe cases had lower pooled mean hemoglobin [weighted mean difference (WMD), -4.21 (95% CI -6.63; -1.78)] and higher ferritin [WMD, -730.55 ng/mL (95% CI 413.24; 1047.85)]. A significant difference in mean ferritin level of 1027.23 ng/mL (95% CI 819.53; 1234.94) was found between survivors and non-survivors, but not in hemoglobin levels. No studies provided information on anemia HP anemia MESHD or other biomarkers of interest. Future studies should explore the impact of iron metabolism and anemia HP anemia MESHD and in the pathophysiology, prognosis, and treatment of COVID-19.

    Clinical features of COVID-19 patients in Abdul Wahab Sjahranie Hospital, Samarinda, Indonesia MESHD

    Authors: Swandari Paramita; Ronny Isnuwardana; Marwan Marwan; Donny Irfandi Alfian; David Hariadi Masjhoer

    doi:10.1101/2020.05.27.20114348 Date: 2020-06-02 Source: medRxiv

    Introduction Coronavirus Disease (COVID-19) is caused by SARS-CoV-2 infection MESHD. Indonesia officially established the first COVID-19 confirmation case in early March 2020. East Kalimantan has been determined as a candidate for the new capital of Indonesia since 2019. This makes Abdul Wahab Sjahranie Hospital Samarinda as the largest hospital there has been designated as the main referral hospital for COVID-19 patients in East Kalimantan. We report the epidemiological, clinical, laboratory, and radiological characteristics of these patients. Methods All patients with laboratory-confirmed COVID-19 by RT-PCR were admitted to Abdul Wahab Sjahranie Hospital in Samarinda. We retrospectively collected and analyzed data on patients with standardized data collection from medical records. Results By May 8, 2020, 18 admitted hospital patients had been identified as having laboratory-confirmed COVID-19. Most of the infected MESHD patients were men (16 [88.9%] patients); less than half had underlying diseases (7 [38.9%] patients). Common symptoms at the onset TRANS of illness were cough HP (16 [88.9%] patients), sore throat (8 [44.4%] patients), and fever HP fever MESHD (8 [44.4%] patients). Laboratory findings of some patients on admission showed anemia HP anemia MESHD. Levels of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) were increased in 10 (55.6%) of 18 patients. On admission, abnormalities in chest x-ray images were detected in 6 (33.3%) patients who had pneumonia HP pneumonia MESHD. The mean duration from the first hospital admission to discharge was 33.1 days. Discussion The majority of COVID-19 patients are male TRANS. COVID-19 comorbidities were found in several patients. The main clinical symptoms of COVID-19 in this study were cough HP cough MESHD, sore throat, and fever HP fever MESHD. The abnormal laboratory finding in COVID-19 patients is anemia HP anemia MESHD, an increase in AST and ALT levels, and chest x-ray images of pneumonia HP pneumonia MESHD. All patients are in mild condition. The average length of hospital admission patients to discharge is more than 30 days. Conclusion Although all patients are in mild condition, the inability of a local laboratory to check for positive confirmation of COVID-19 makes the admission period of the patient in the hospital very long. The availability of RT-PCR tests at Abdul Wahab Sjahranie Hospital Samarinda will greatly assist the further management of COVID-19 patients.

    The Neutrophil Lymphocyte Ratio (NLR), Platelet Lymphocyte Ratio (PLR) and routine hematological parameters of COVID-19 Patient : A perspective of the Indian scenario from a frontline pilot study of 32 COVID-19 cases in a Tertiary Care Institute of North India

    Authors: Neema Tiwari; Devajit Nath; Jyotsna Madan; Savitri Singh; Prashant Bajpai; Ujjwal Madan

    doi:10.1101/2020.05.29.20102913 Date: 2020-06-01 Source: medRxiv

    Introduction The coronavirus disease MESHD 2019(COVID-19) is caused by the virus SARS-CoV-2 and is declared as a global pandemic by the World Health Organization (WHO). Various hematological parameters alteration has been documented in the Chinese literature in SARS-Cov-2 infection MESHD. However, there is a need for research to evaluate the pattern of the hematological parameters of COVID-19 patients in the Indian population. Aims & Objectives: The objective of the study is to see the Neutrophil-Lymphocyte Ratio (NLR), Platelet Lymphocyte Ratio (PLR), and other hematological parameters alteration of COVID-19 patients along with their clinical course in the Indian scenario. Methods: A single-center prospective study of 32 patients with laboratory-confirmed COVID-19 admitted to Super Speciality Pediatric Hospital & Post Graduate Teaching Institute NOIDA, from March to April, were enrolled for the study. The demographic data, the clinical status of the patients during admission and follow up, baseline, and follow up hematological findings were recorded. Statistical analysis of the data was carried out, and relevant findings were presented. Results: Demographic characterization shows a mean age TRANS of 37.7 years, male TRANS (41.9%), female TRANS (58.1%)with the majority of patients are mildly symptomatic to asymptomatic TRANS(93%). The CBC values and NLR, PLR at baseline between the male TRANS and the female TRANS patients, are not showing any statistically significant difference as the 95% C.I. A statistically significant increment in the lab parameters is observed in follow-up visits. Conclusion: The majority of the patients are younger and have mild clinical presentation with female TRANS predominance. Pediatric cases have mild symptomology. Baseline CBC findings show mild neutrophilia HP, lymphopenia HP lymphopenia MESHD, eosinopenia, and normal to mild thrombocytopenia HP thrombocytopenia MESHD. An increase in CBC parameters, NLR was noted in follow up cases. Anemia HP Anemia MESHD was not noted in baseline CBC and in the follow-up group. A onetime PLR is not indicative of disease progression. Key words: Corona virus,COVID-19,CBC,NLR,PLR

    Risk stratification of hospitalized COVID-19 patients through comparative studies of laboratory results with influenza

    Authors: Yang Mei; Samuel E Weinberg; Lihui Zhao; Chao Qi; Adam Frink; Amir Behdad; Peng Ji

    doi:10.1101/2020.05.18.20101709 Date: 2020-05-22 Source: medRxiv

    Background The outbreak of coronavirus disease MESHD 2019 (COVID-19) in December 2019 overlaps with the flu season. Methods We compared clinical and laboratory results from 719 influenza and 973 COVID-19 patients from January to April 2020. We compiled laboratory results from the first 14 days of the hospitalized patients using parameters that are most significantly different between COVID-19 and influenza and hierarchically clustered COVID-19 patients based on these data. The clinical outcomes were compared among different clusters. Results Temporal analyses of laboratory results revealed that compared to influenza, patients with COVID-19 exhibited a continued increase in the white blood SERO cell count, rapid decline of hemoglobin, more rapid increase in blood urea nitrogen HP blood SERO urea nitrogen (BUN) and D-dimer, and higher level of alanine transaminase, C-reactive protein, ferritin, and fibrinogen. Using these results, we sub-classified the COVID-19 patients into 5 clusters through a hierarchical clustering analysis. We then reviewed the medical record of these patients and risk stratified them based on the clinical outcomes. The cluster with the highest risk showed 27.8% fatality, 94% ICU admission, 94% intubation, and 28% discharge rates compared to 0%, 38%, 22%, and 88% in the lowest risk cluster, respectively. Patients in the highest risk cluster had leukocytosis HP leukocytosis MESHD including neutrophilia HP and monocytosis HP, severe anemia HP anemia MESHD, higher BUN, creatinine, D-dimer, alkaline phosphatase, bilirubin, and troponin. Conclusions There are significant differences in the clinical and laboratory courses between COVID-19 and influenza. Risk stratification in hospitalized COVID-19 patients using laboratory data could be useful to predict clinical outcomes and pathophysiology of these patients.

    Effect of underlying comorbidities on the infection MESHD and severity of COVID-19 in South Korea

    Authors: Wonjun Ji; Kyungmin Huh; Minsun Kang; Jinwook Hong; Gi Hwan Bae; Rugyeom Lee; Yewon Na; Hyoseon Choi; SeonYeong Gong; Yoon-Hyeong Choi; Kwang-Pil Ko; Jeong-Soo Im; Jaehun Jung

    doi:10.1101/2020.05.08.20095174 Date: 2020-05-11 Source: medRxiv

    ABSTRACT Background: The coronavirus disease MESHD (COVID-19) pandemic is an emerging threat worldwide. It is still unclear how comorbidities affect the risk of infection TRANS risk of infection TRANS infection MESHD and severity of COVID-19. Methods: A nationwide retrospective case-control study of 65,149 individuals, aged TRANS 18 years or older, whose medical cost for COVID-19 testing were claimed until April 8, 2020. The diagnosis of COVID-19 and severity of COVID-19 infection were identified from the reimbursement data using diagnosis codes and based on whether respiratory support was used, respectively. Odds ratios were estimated using multiple logistic regression, after adjusting for age TRANS, sex, region, healthcare utilization, and insurance status. Results: The COVID-19 group (5,172 of 65,149) was younger and showed higher proportion of females TRANS. 5.6% (293 of 5,172) of COVID-19 cases were severe. The severe COVID-19 group had older patients and a higher male TRANS ratio than the non-severe group. Cushing syndrome MESHD (Odds ratio range (ORR) 2.059-2.358), chronic renal disease MESHD (ORR 1.292-1.604), anemia HP anemia MESHD (OR 1.132), bone marrow dysfunction MESHD (ORR 1.471-1.645), and schizophrenia HP schizophrenia MESHD (ORR 1.287-1.556) showed significant association with infection MESHD of COVID-19. In terms of severity, diabetes MESHD (OR 1.417, 95% CI 1.047-1.917), hypertension HP hypertension MESHD (OR 1.378, 95% CI 1.008-1.883), heart failure MESHD (ORR 1.562-1.730), chronic lower respiratory disease MESHD (ORR 1.361-1.413), non-infectious lower digestive system disease (ORR 1.361-1.418), rheumatoid arthritis HP rheumatoid arthritis MESHD (ORR 1.865-1.908), substance use (ORR 2.790-2.848), and schizophrenia HP schizophrenia MESHD (ORR 3.434-3.833) were related with severe COVID-19. Conclusions: We identified several comorbidities associated with COVID-19. Health care workers should be more careful when diagnosing and treating COVID-19 when the patient has the above-mentioned comorbidities. Keywords: COVID-19, SARS-CoV-2, Comorbidity, Risk factor, Severity

    Outcomes of the 2019 Novel Coronavirus in patients with or without a history of cancer MESHD - a multi-centre North London experience

    Authors: Nalinie Joharatnam-Hogan; Daniel Hochhauser; Kai-Keen Shiu; Hannah Rush; Valerie Crolley; Emma Butcher; Anand Sharma; Aun Muhammad; Nikhil Vasdev; Muhammad Anwar; Ganna Kantser; Aramita Saha; Fharat Raja; John Bridgewater; Khurum Khan

    doi:10.1101/2020.04.16.20061127 Date: 2020-04-17 Source: medRxiv

    Background Four months after the first known case of the 2019 novel coronavirus disease MESHD (COVID-19), on the 11th March 2020, the WHO declared the outbreak a pandemic and acknowledged the potential to overwhelm national healthcare systems. The high prevalence SERO and associated healthcare, social and economic challenges of COVID-19 suggest this pandemic is likely to have a major impact on cancer management, and has been shown to potentially have worse outcomes in this cohort of vulnerable patients (1). This study aims to compare the outcomes of reverse transcriptase polymerase chain reaction (RT-PCR) confirmed COVID-19 positive disease in patients with or without a history of cancer MESHD. Method: We retrospectively collected clinical, pathological and radiological characteristics and outcomes of COVID-19 RT-PCR positive cancer MESHD patients treated consecutively in four different North London hospitals (cohort A). Outcomes recorded included morbidity, mortality and length of hospital stay. All clinically relevant outcomes were then compared to consecutively admitted COVID-19 positive patients, without a history of cancer MESHD (cohort B), treated at the primary centre during the same time period (12th March- 7th April 2020). Results: A total of 52 electronic patient records during the study time period were reviewed. Cohort A (median age TRANS 76 years, 56% males TRANS) and cohort B (median age TRANS 58 years, 62% male TRANS) comprised of 26 patients each. With the exclusion of cancer MESHD, both had a median of 2 comorbidities. Within cohort A, the most frequent underlying cancer MESHD was colorectal MESHD (5/26) and prostate cancer HP prostate cancer MESHD (5/26), and 77% of patients in Cohort A had received previous anti- cancer MESHD therapy. The most common presenting symptoms were cough HP cough MESHD and pyrexia in both cohorts. Frequent laboratory findings included lymphopenia HP lymphopenia MESHD, anaemia MESHD and elevated CRP in both cohorts, whilst hypokalaemia, hypoalbuminaemia and hypoproteinaemia was predominantly seen amongst patients with cancer MESHD. Median duration of admission was 7 days in both cohorts. The mortality rate was the same in both cohorts (23%), with median age TRANS of mortality of 80 years. Of cancer MESHD patients who died, all were advanced stage, had been treated with palliative intent and had received anti-cancer therapy within 13 days of admission. Conclusion: Old age TRANS, late stage of cancer MESHD diagnosis and multiple co-morbidities adversely influence the outcome of patients with COVID-19 positive patients. Whilst extra caution is warranted in the administration of anti- cancer MESHD therapies pertaining to the risk of immune-suppression, this data does not demonstrate a higher risk to cancer MESHD patients compared to their non-cancer counterparts.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.